Leukemia Therapeutics is focused on developing innovative antibody-targeted therapies aimed at improving the survival and quality of life for patients with various forms of leukemia, including Acute Myeloid Leukemia, Hairy Cell Leukemia, and Adult T-Cell Leukemia. The company emphasizes its commitment to accelerating the discovery of these novel treatments by leveraging a collaborative approach that integrates academic research with pharmaceutical expertise. This partnership within the open science ecosystem allows for a more efficient and effective development process for new leukemia therapies.

The company's proprietary discovery platform plays a crucial role in identifying therapeutic antibody targets. This platform is based on the correction of aberrantly expressed intracellular signaling molecules found on the surface of leukemia cells. By focusing on these specific targets, Leukemia Therapeutics aims to create more effective treatments that can specifically address the unique characteristics of leukemia, ultimately leading to better patient outcomes.

United States

Leukemia Therapeutics is a biotech company that discovers and brings leukemia drugs to market. The company focuses on Acute Myeloid Leukemia (AML),

Leukemia Therapeutics

Company Details